The trials of the Pfizer COVID-19 vaccine might have been flawed, the science journal BMJ
Pfizer declared that the vaccine has shown 95% efficiency in preventing COVID-19 contagion during the clinical tests as the meds had been authorized in dozens of countries across the globe.
"A regional director who was employed at the research organization Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial," the BMJ publication reads.
The investigation was launched after the fired regional director of the Ventavia Research Group Brook Jackson gave the BMJ editorial documents and other information from the Texas lab. Jackson herself took part in the trials and was responsible for the final results.
She has repeatedly called upon the management of the lab to improve the conditions of the work and pay close attention to the trials.
Jackson claims these inconsistencies made the Pfizer executive board worried about the inspections of the US Food and Drug Administration (FDA) and other regulatory agencies, therefore the company falsified and covered up the trials data.
Brook filed a complaint to FDA but on the same day, Venavia dismissed its regional director.
Pfizer started vaccine trials back in April 2020 as the first two stages were completed in autumn 2020. The third one launched in November 2020 and continues to this date.
Earlier on Wednesday, the Centers for Disease Control and Prevention agency (CDC)